Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by amorakon Jun 06, 2007 1:33pm
397 Views
Post# 12901594

RE: tbor

RE: tborOk, tbor, Oppenheimer bought the financing. To whom are they selling it? Is it 1 name or 2 names, corporate, private? What if it's a cheap and undisclosed way for a pharma to buy the stock, a way that's even unknown to Oppenheimer? Or is it a way for RVX to put shares in the hands of special friends? Or does RVX really need the money? I don't know but I suspect they need the money. It may even be used to cash up the RVX Therapeutics spinoff if that's what it takes to get the job done. However, I doubt the spinoff scenario because the spinoff contains NexVas for Alzheimer's although it could be "sold" back to RVX for a big portion of the financing. I would expect all of the NexVas parts will be sold together in RVX for reasons discussed here before. And why not just get a loan as you suggest? Because who in his right mind would play for a 6 or 8 (or 15) percent rate of return when they can have the rate plus conversion privileges! Who would loan money to a company with no revenue but with high value appreciation prospects? Nobody, that's who! My goodness, they can even convert the interest to stock and they can short the stock and cover with the conversion stock. I wouldn't loan RVX a nickle, nor would anybody else in his right mind.
Bullboard Posts